The Pharma Times | Pharma & Health Care News Portal

Receive USD 4 Million Award from The Wellcome Trust for Development and Clinical Trials Hyderabad, India, June 18, 2012: Bharat Biotech and The University of Maryland Center for  Vaccine Development (“CVD”) announced today a significant milestone achievement– receiving a USD  4 Million Strategic Translation Award from The Wellcome Trust for clinical development of a new  conjugate vaccine including initial clinical trials beginning in three years to prevent the potentially  lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS).   NTS have emerged as an important cause of invasive bloodstream infection in sub-Saharan Africa,  among young children with malaria and malnutrition, and among adults with HIV. Strains of nontyphoidal Salmonella (“NTS”) that can cause systemic disease such as meningitis or sepsis are  particularly common in sub-Saharan Africa; approximately 20 to 30% of children with such invasive  NTS infections die.